Neuronetics Inc
NASDAQ:STIM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neuronetics Inc
Cash & Cash Equivalents
Neuronetics Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuronetics Inc
NASDAQ:STIM
|
Cash & Cash Equivalents
$28.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash & Cash Equivalents
$2B
|
CAGR 3-Years
51%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
19%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash & Cash Equivalents
$2.9B
|
CAGR 3-Years
50%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash & Cash Equivalents
$4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash & Cash Equivalents
$8.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash & Cash Equivalents
$3.4B
|
CAGR 3-Years
29%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
Neuronetics Inc
Glance View
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
See Also
What is Neuronetics Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
28.1m
USD
Based on the financial report for Dec 31, 2025, Neuronetics Inc's Cash & Cash Equivalents amounts to 28.1m USD.
What is Neuronetics Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-11%
Over the last year, the Cash & Cash Equivalents growth was 52%. The average annual Cash & Cash Equivalents growth rates for Neuronetics Inc have been -26% over the past three years , -11% over the past five years .
